# New Genotype-guided Treatment in Newly Diagnosed PTCL

> **NCT07706959** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 108 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma (PTCL)

## Interventions

- **DRUG:** Azacitidine plus Selinexor with CHOP
- **DRUG:** Decitabine plus Selinexor with CHOP
- **DRUG:** Zeprumetostat plus chidamide with CHOP
- **DRUG:** Azacitidine plus Golidocitinib with CHOP
- **DRUG:** CHOP

## Key facts

- **NCT ID:** NCT07706959
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-01
- **Final completion:** 2029-07
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2026-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07706959

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07706959, "New Genotype-guided Treatment in Newly Diagnosed PTCL". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07706959. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*